ASXChange of Director's Interest Notice
director_dealing announcement
AGN
Pharmaceuticals, Biotechnology & Life Sciences
Argenica Therapeutics
- Short interest
- 0.01%
- +0.01 pp 30d
- as of 3 July 2026
- Reported shorts
- 15.2K
- Shares on issue
- 128.457M
Argenica Therapeutics (AGN) News
Latest articles and price-sensitive announcements with AI sentiment classification.
KalkineWhat could AGN (ASX:AGN) reveal after its AGM update?
Highlights AGN has issued a fresh corporate disclosure covering its AGM date and the closing date for director nominations. The announcement places attention on an important governance and shareholder timetable. Further company communication around the AGM may provide additional context beyond the current procedural update. Australian equities continue to generate a steady stream of company-specific announcements, with corporate-calendar updates often providing an important reference poi...
AGM Date & Closing Date for Director Nominations
other announcement
Concussion Data Selected for Neurotrauma Congress
other announcement
Google NewsArgenica Therapeutics Limited (ASX:AGN) Share Price Falls 5.56% as Stock Trades Within Daily Range - Kalkine
Argenica Therapeutics Limited (ASX:AGN) Share Price Falls 5.56% as Stock Trades Within Daily Range Kalkine
Argenica Therapeutics Ltd (ASX: AGN) Share Price Update: Stock Rises as Health Care Sector Closes Lower - Kalkine
Argenica Therapeutics Ltd (ASX: AGN) Share Price Update: Stock Rises as Health Care Sector Closes Lower Kalkine
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Small CapsARG007 Shows Significant Neuroprotection in Concussion Study
other announcement
ARG007 (Xaranetide) Completes All Three FDA Requested Assays
other announcement
Why Argenica Therapeutics (ASX:AGN) Shares Are Back in Focus Today? - Kalkine
Why Argenica Therapeutics (ASX:AGN) Shares Are Back in Focus Today? Kalkine
IND Application Advanced With Successful Completion of Assay
other announcement
Clinical Advisory Committee Established to Advance Phase 2b
other announcement
Presentations at European Stroke Organisation Conference
other announcement
Argenica Receives $3.97m R&D Tax Incentive Cash Rebate
other announcement
Investor Presentation - Euroz Hartleys Healthcare Conference
other announcement
AI Analysis Reveals Efficacy In Severe Stroke Patients
other announcement
Positive TNK Study Results Fulfil Key FDA Requirement
other announcement
ARG-007 Efficacious Dose Validated in New Preclinical Study
other announcement
Investor Presentation - Cannacord Dug & Device Conference
other announcement
Phase 2 Trial Promising Improvements in Functional Outcomes
other announcement
Date of AGM & Closing Date for Director Nominations
other announcement
Topline Phase 2 Trial Results of ARG-007 in AIS Patients
other announcement
Argenica Appoints Vice President of Regulatory Affairs
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement